The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Joseph J. Ciaffoni net worth and biography

Joseph Ciaffoni Biography and Net Worth

Pres of Collegium Pharmaceutical

Joe Ciaffoni was appointed President and Chief Executive Officer of Collegium Pharmaceutical in July 2018. Mr. Ciaffoni joined Collegium Pharmaceutical in May 2017 as Executive Vice President and Chief Operating Officer. Prior to joining Collegium, he served as President, U.S. Branded Pharmaceuticals of Endo International plc. Before that, Mr. Ciaffoni held various positions of increasing responsibility at Biogen, including Senior Vice President, Global Specialty Medicines Group, Senior Vice President, U.S. Commercial and Vice President, U.S. Neurology Field Operations and Marketing. Prior to joining Biogen, he was Executive Vice President and Chief Operating Officer of Shionogi Inc. and President of Shionogi Pharmaceuticals. Mr. Ciaffoni also previously served as Vice President, Sales for Schering-Plough (now Merck) and held several commercial leadership roles at Sanofi-Synthelabo (now Sanofi) and Novartis. Mr. Ciaffoni received a B.A. in Communications and an M.B.A. from Rutgers.

How old is Joseph J. Ciaffoni?: Mr. Ciaffoni is currently 52 years old. There are 4 older executives and no younger executives at Collegium Pharmaceutical. The oldest executive at Collegium Pharmaceutical is Dr. Thomas B. Smith FAAFP, M.D., Executive VP & Chief Medical Officer, who is 63 years old. Learn More on Joseph J. Ciaffoni's age.
How do I contact Joseph J. Ciaffoni?: The corporate mailing address for Mr. Ciaffoni and other Collegium Pharmaceutical executives is 100 Technology Center Drive, Stoughton MA, 02072. Collegium Pharmaceutical can also be reached via phone at (781) 713-3699 and via email at [email protected]. Learn More on Joseph J. Ciaffoni's contact information.
Has Joseph J. Ciaffoni been buying or selling shares of Collegium Pharmaceutical?: Joseph J. Ciaffoni has not been actively trading shares of Collegium Pharmaceutical within the last three months. Learn More on Joseph J. Ciaffoni's trading history.
Who are Collegium Pharmaceutical's active insiders?: Collegium Pharmaceutical's insider roster includes Joseph Ciaffoni (Pres), Scott Dreyer (EVP), Michael Heffernan (Director), Shirley Kuhlmann (EVP), and Colleen Tupper (Exec. VP & CFO ). Learn More on Collegium Pharmaceutical's active insiders.
Are insiders buying or selling shares of Collegium Pharmaceutical?: During the last year, insiders at the specialty pharmaceutical company sold shares 9 times. They sold a total of 202,376 shares worth more than $6,618,056.46. The most recent insider tranaction occured on September, 13th when EVP Thomas B Smith sold 9,593 shares worth more than $351,295.66. Insiders at Collegium Pharmaceutical own 4.0% of the company. Learn More about insider trades at Collegium Pharmaceutical.
Information on this page was last updated on 9/13/2024.

Joseph J. Ciaffoni Insider Trading History at Collegium Pharmaceutical

Joseph J. Ciaffoni Buying and Selling Activity at Collegium Pharmaceutical

Collegium Pharmaceutical Company Overview

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Today's Range

Now: $29.58

$29.17

$30.65

50 Day Range

MA: $36.36

$29.58

$41.86

2 Week Range

Now: $29.58

$24.61

$42.29

Volume

605,403 shs

Average Volume

418,211 shs

Market Capitalization

$953.96 million

P/E Ratio

12.75

Dividend Yield

N/A

Beta

0.95

Financial Prophecy

From Porter & Company | Ad